Nitrosamines Analysis in Pharmaceuticals - Consumables workflow ordering guide
Guides | 2021 | Agilent TechnologiesInstrumentation
GC columns, Consumables
IndustriesPharma & Biopharma
ManufacturerAgilent Technologies
Key wordsnitrosamine, nitrosamines, ndma, ndea, mylist, favorite, neipa, ndipa, drug, ppm, items, inlet, click, replacement, ndba, supplies, your, gas, parameters, collar, temperature, standards, purifier, lod, quadrupole, nitrosodiethylamine, loq, mode, impurities, product, substance, tightening, nitrosodimethylamine, products, column, find, liners, nut, caps, fill, download, self, list, header, split, filters, impurity, selector, all, oven
Similar PDF
Nitrosamine Impurities Application Guide - Confidently Detect and Quantify Mutagenic Impurities in APIs and Drug Products
2020|Agilent Technologies|GuidesPresentations
Nitrosamine Impurities Application Guide Confidently Detect and Quantify Mutagenic Impurities in APIs and Drug Products Sartan-Based Losartan Valsartan Candesartan Telmisartan Metformin Ranitidine Nitrosamines are formed by chemical reactions that occur during API manufacturing whether from starting materials, intermediates, reactants, reuse…
Key words
back, backndma, ndmaneipa, neipafda, fdandipa, ndipandea, ndeandba, ndbametformin, metforminnitrosamine, nitrosamineintroduction, introductionapi, apivalsartan, valsartanquant, quantbest, bestcandesartan
Analysis of Five Nitrosamine Impurities in Drug Products and Drug Substances Using Agilent GC/MS/MS Instrumentation
2020|Agilent Technologies|Applications
Application Note Pharma & Biopharma Analysis of Five Nitrosamine Impurities in Drug Products and Drug Substances Using Agilent GC/MS/MS Instrumentation Authors Soma Dasgupta, Lalith Hansoge, Vivek Dhyani, Samir Vyas, and Melissa Churley Agilent Technologies, Inc. Abstract This application note highlights…
Key words
relative, relativeresponses, responsesndba, ndbaneipa, neipandipa, ndipandma, ndmandea, ndeaotr, otrstd, stdfda, fdacounts, countsconcentration, concentrationacquisition, acquisitiondrug, drugimpurities
Overcoming the challenges of nitrosamine impurities in drugs
2020|Thermo Fisher Scientific|Technical notes
CASE STUDY 73263 Overcoming the challenges of nitrosamine impurities in drugs What pharmaceutical QA/QC laboratories need to know: Advanced GC-MS capabilities for cGMP nitrosamine testing Why we need to analyze nitrosamine impurities in drugs Unacceptable levels of nitrosamine impurities were…
Key words
min, minndma, ndmandea, ndeanitrosamine, nitrosamineneipa, neipatime, timetemperature, temperatureimpurities, impuritiesorbitrap, orbitrapaquisition, aquisitionmass, massexactive, exactivesource, sourceloop, loopkpa
Overcoming the challenges of nitrosamine impurities in drugs
2020|Thermo Fisher Scientific|Others
CASE STUDY 73263 Overcoming the challenges of nitrosamine impurities in drugs What pharmaceutical QA/QC laboratories need to know: Advanced GC-MS capabilities for cGMP nitrosamine testing Why we need to analyze nitrosamine impurities in drugs Unacceptable levels of nitrosamine impurities were…
Key words
min, minndma, ndmandea, ndeanitrosamine, nitrosamineneipa, neipatime, timetemperature, temperatureimpurities, impuritiesorbitrap, orbitrapaquisition, aquisitionmass, massexactive, exactivesource, sourceloop, loopkpa